d) correlating the decrease in the expression of Notch-1 when compared with the expression of Notch-1 from the untreated or placebo treated control cell to the sensitivity of the cancer cell to a Wnt inhibitor.

4. The method of any one of claims 1 to 3, wherein the Notch1 has mutation in extracellular domain.

5. The method of any one of claims 1 to 4, wherein cancer is a head and neck squamous cell carcinoma.

6. The method of any one of claims 1 to 5, wherein the cancer shows differential expression of Axin2, LEF1 and/or NKD1 compared to the expression in a cancer sample that is sensitive to a Wnt inhibitor.

7. The method of any one of claims 1 to 6, wherein expression or gene expression is DNA expression, DNA copy number, mRNA expression, cDNA expression, protein transcription, protein expression, DNA modification, cDNA modificaiton, mRNA modification, protein modification, DNA function, cDNA function, mRNA function, protein function, DNA mutation, cDNA mutation, mRNA mutation, protein mutation, or combinations thereof; preferably is DNA mutation.

8. Use of a Wnt inhibitor named 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cancer in a patient who has been found to be sensitive to the Wnt inhibitor, the method comprising:
a) being provided with a cancer sample obtained from a cancer patient
b) measuring differential gene expression of at least one biomarker which is Notch-1, in the cancer sample;
c) comparing the differential gene expression of the at least one biomarker with gene expression of a biomarker in a control sample; and
d) determining sensitivity of the patient to the Wnt inhibitor based on the reduced expression, or decreased activity or function of the at least one biomarker when compared to the control.

9. Use of a Wnt inhibitor named 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a cancer in a patient, wherein the patient is selected on the basis of:

a) measuring differential gene expression of at least one biomarker which is Notch-1, in a cancer sample obtained from the patient;

b) comparing the differential gene expression of the at least one biomarker with gene expression of the biomarker in a control sample;

c) determining sensitivity of the patient to the Wnt inhibitor based on the reduced expression, or decreased activity or function of the at least one biomarker when compared to the control; and

d) selecting the patient that is sensitive to the Wnt inhibitor;

and 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, is to be administered to the patient that is identified as sensitive or that is likely to respond to the treatment with the Wnt inhibitor.

10. Use of a Wnt inhibitor named 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient having differential gene expression of at least one biomarker which is Notch-1 as compared to a control gene expression, wherein the differential gene expression correlates with the patient being sensitive to the Wnt inhibitor when the expression of the at least one biomarker which is Notch-1 is reduced, or its activity or function decreased when compared to the control.

11. Use of a pharmaceutical composition comprising a Wnt inhibitor named 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient, wherein the patient is selected on the basis of showing a gene expression of at least one biomarker which is Notch-1 in a cancer cell sample obtained from said patient compared to a normal control cell sample, wherein the differential gene expression correlates with the patient being sensitive to

the Wnt inhibitor when the expression of the at least one biomarker which is Notch-1 is reduced, or its activity or function decreased when compared to the control.

12. Use of a pharmaceutical composition comprising a Wnt inhibitor named 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient showing differential gene expression of at least one biomarker which is Notch-1 as compared to a control gene expression, wherein the differential gene expression correlates with the patient being sensitive to the Wnt inhibitor when the expression of the at least one biomarker which is Notch-1 is reduced, or its activity or function decreased when compared to the control.

13. The use according to any one of claims 8 to 12, wherein the Notch1 has mutation in extracellular domain.

14. The use according to any one of claims 8 to 13, wherein cancer is a head and neck squamous cell carcinoma.

15. The use according to claim 8 to 14, wherein the cancer shows a differential expression of Axin2, LEF1 and/or NKD1 compared to the expression in a cancer sample that is sensitive to a Wnt inhibitor.

16. Use of a Wnt inhibitor named 2-[5-methyl-6-(2-methylpyridin-4-yl)pyridin-3-yl]-N-[5-(pyrazin-2-yl)pyridin-2-yl]acetamide, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of head and neck squamous cell carcinoma, wherein the cancer shows a differential gene expression of at least one biomarker which is Notch-1 compared to a control gene expression, wherein the differential gene expression correlates with the cancer being sensitive to the Wnt inhibitor.

17. Use according to any one of claims 8 to 16, wherein expression or gene expression is DNA expression, DNA copy number, mRNA expression, cDNA expression, protein transcription, protein expression, DNA modification, cDNA modificaiton, mRNA modification, protein modification, DNA function, cDNA function, mRNA function,

protein function, DNA mutation, cDNA mutation, mRNA mutation, protein mutation, or combinations thereof; preferably is DNA mutation.